教員紹介

埴岡 伸光
Hanioka Nobumitsu

所属・肩書

健康薬学科/公衆衛生学研究室(教授)

最終学歴

九州大学大学院 薬学研究科 博士課程修了(衛生化学・裁判化学専攻)

取得学位

薬学博士(九州大学)

所属学会

日本薬学会、日本薬物動態学会、日本毒性学会

現在の専門分野

薬物代謝学、衛生薬学、分子毒性学

現在の研究課題

●薬物代謝酵素の分子的・機能的多様性
●環境化学物質の代謝の個人差
●植物エストロゲンの生体内運命
●食品-医薬品の相互作用の分子機序

主要研究業績

●変異型薬物代謝酵素の機能変化
●内分泌かく乱化学物質の代謝
●植物エストロゲンの代謝

最近の研究業績

1.Hanioka N*,Isobe T, Ohkawara S, Ochi S, Tanaka-Kagawa T, Jinno H. Hydrolysis of di(2-ethylhexyl) phthalate in humans, monkeys, dogs, rats, and mice: an in vitro analysis using liver and intestinal microsomes. Toxicol In Vitro, in press. doi: 10.1016/j.tiv.2018.10.006.

2.Hanioka N*, Ohkawara S, Isobe T, Ochi S, Tanaka-Kagawa T, Jinno H. Regioselective glucuronidation of daidzein in liver and intestinal microsomes of humans, monkeys, rats, and mice. Arch Toxicol 92(9):2809–2017.doi: 10.1007/s00204-018-2265-1.

3.Isobe T, Ohkawara S, Ochi S, Tanaka-Kagawa T, Jinno H, Hanioka N*. Naringenin glucuronidation in liver and intestine microsomes of humans, monkeys, rats, and mice. Food Chem Toxicol 2018;111:417–422. doi: 10.1016/j.fct.2017.11.057.

4.Miyata-Nozaka Y, Mohd Zain S, Taguchi M, Shigeyama M, Isobe T, Hanioka N*. Carbamazepine 10,11-epoxidation in human liver microsomes: influence of the CYP3A5*3 polymorphism. Pharmazie 2017;72 (12):747–450. doi: 10.1691/ph.2017.7754.

5.Isobe T, Ohkawara S, Tanaka-Kagawa T, Jinno H, Hanioka N*. Hepatic glucuronidation of 4-tert-octylphenol in humans: inter-individual variability and responsible UDP-glucuronosyltransferase isoforms. Arch Toxicol 2017;91(11):3543–3550. doi: 10.1007/s00204-017-1982-1.

6.Hanioka N*, Isobe T, Ohkawara S, Tanaka-Kagawa T, Jinno H. Glucuronidation of 4-tert-octylphenol in humans, monkeys, rats, and mice: an in vitro analysis using liver and intestine microsomes. Arch Toxicol 2017;91(3):1227–1232. doi: 10.1007/s00204-016-1800-1.

7.Hanioka N*, Kinashi Y, Tanaka-Kagawa T, Isobe T, Jinno H. Glucuronidation of mono(2-ethylhexyl) phthalate in humans: roles of hepatic and intestinal UDP-glucuronosyltransferases. Arch Toxicol 2017 91(2):689–698. doi: 10.1007/s00204-016-1708-9.

8.Hanioka N*, Isobe T, Kinashi Y, Tanaka-Kagawa T, Jinno H. Hepatic and intestinal glucuronidation of mono(2-ethylhexyl) phthalate, an active metabolite of di(2-ethylhexyl) phthalate, in humans, dogs, rats and mice: an in vitro analysis using microsomal fractions. Arch Toxicol 2016;90(7):1651–1657. doi: 10.1007/s00204-015-1619-1.

9.Kishi N, Takasuka A, Kokawa Y, Isobe T, Taguchi M, Shigeyama M, Murata M, Suno M, Hanioka N*. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8, and UGT1A9. Xenobiotica 2016;46(4):289–295. doi: 10.3109/00498254.2015.1074301.

10.Miyake Y, Hirose R, Isobe T, Hanioka N*. Molecular cloning and functional analysis of minipig UDP-glucuronosyltransferase 1A6. Xenobiotica 2016;46(3):193–199. doi: 10.3109/00498254.2015.1060373.

11.Isobe T, Kofuji K, Okada K, Fujimori J, Murata M, Shigeyama M, Hanioka N, Murata Y. Adsorption of histones on natural polysaccharides: the potential as agent for multiple organ failure in sepsis. Int J Biol Macromol. 2016: 84:54–57. doi: 10.1016/j.ijbiomac.2015.11.029.

12.Mukai M, Isobe T, Okada K, Murata M, Hanioka N*. Species and sex differences in propofol glucuronidation in liver microsomes of humans, monkeys, rats and mice. Pharmazie 2015;70 (7):466–470. doi: 10.1691/ph.2015.5525.

13.Mukai M, Tanaka S, Yamamoto K, Murata M, Okada K, Isobe T, Shigeyama M, Hichiya H, Hanioka N*. In vitro glucuronidation of propofol in microsomal fractions from human liver, intestine and kidney: tissue distribution and physiological role of UGT1A9. Pharmazie 2014;69(11):829–832. doi: 10.1691/ph.2014.4564.

14.Yamamoto K, Mukai M, Nagaoka K, Hayashi K, Hichiya H, Okada K, Murata M, Shigeyama M, Narimatsu S, Hanioka N*. Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. Eur J Drug Metab Pharmacokinet 2014;39(3):195–202. DOI 10.1007/s13318-014-0177-x

15.Takahara Y, Kinashi Y, Takahara Y, Hichiya H, Okada K, Murata M, Shigeyama M, Hanioka N*. Butylbenzyl phthalate hydrolysis in liver microsomes of humans, monkeys, dogs, rats and mice. Biol Pharm Bull 2014;37(4):703–706.

16.Kuze J, Mutoh T, Takenaka T, Oda N, Hanioka N, Narimatsu S. Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam. Xenobiotica 2013;43(7):598–606. doi: 10.3109/00498254.2012.751517.

17.Kokawa Y, Kishi N, Jinno H, Tanaka-Kagawa T, Narimatsu S, Hanioka N*. Effect of UDP-glucuronosyltransferase 1A8 polymorphism on raloxifene glucuronidation. Eur J Pharm Sci. 2013;49(2):199–205. doi: 10.1016/j.ejps.2013.03.001.

18.Mayumi K, Hanioka N, Masuda K, Koeda A, Naito S, Miyata A, Narimatsu S. Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions. Biochem Pharmacol. 2013;85(8):1182–1194. doi: 10.1016/j.bcp.2013.01.024.

19.Miyake Y, Mayumi K, Jinno H, Tanaka-Kagawa T, Narimatsu S, Hanioka N*. cDNA cloning and functional analysis of minipig UDP-glucuronosyltransferase 1A1. Biol Pharm Bull 2013;36(3):452–461.

20.Hanioka N*, Takahara Y, Takahara Y, Tanaka-Kagawa T, Jinno H, Narimatsu S. Hydrolysis of di-n-butyl phthalate, butylbenzyl phthalate and di(2-ethylhexyl) phthalate in human liver microsomes. Chemosphere 2012;89(9):1112–1117. doi: 10.1016/j.chemosphere.2012.05.095.

21.Nagaoka K, Hanioka N, Ikushiro S, Yamano S, Narimatsu S. The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. Drug Metab Pharmacokinet 2012;27(4):388–397.

22.Hanioka N*, Nonaka Y, Saito K, Kataoka H, Narimatsu S. Effect of aflatoxin B1 on UDP-glucuronosyltransferase mRNA expression in HepG2 cells. Chemosphere 2012;89(5):526–529. doi: 10.1016/j.chemosphere.2012.05.039.

23.Hanioka N*, Tanaka S, Moriguchi Y, Narimatsu S. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes. Pharmacology 2012;90(3–4):117–124. doi: 10.1159/000340020.

24.Hanioka N*, Iwabu H, Hanafusa H, Nakada S, Narimatsu S. Expression and inducibility of UDP-glucuronosyltransferase 1As in MCF-7 human breast carcinoma cells. Basic Clin Pharmacol Toxicol 2012;110(3):253–258. doi: 10.1111/j.1742-7843.2011.00790.x.

25.Narimatsu S, Nakanishi R, Hanioka N, Saito K, Kataoka H. Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: focusing on CYP2A6. Chem Biol Interact 2011;194(2–3): 120–126. doi: 10.1016/j.cbi.2011.09.002.

26.Hanioka N*, Oka H, Nagaoka K, Ikushiro S, Narimatsu S. Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch Toxicol 2011;85(11):1373–1381. doi: 10.1007/s00204-011-0690-5.

27.Hanioka N*, Matsumoto K, Saito Y, Narimatsu S. Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation. Basic Clin Pharmacol Toxicol 2011;108(5):359–362. doi: 10.1111/j.1742-7843.2010.00669.x.

28.Narimatsu S, Nakata T, Shimizudania T, Nagaoka K, Nakura H, Masuda K, Katsu T., Koeda A, Naito S, Yamano S, Miyata A, Hanioka N. Regio- and stereoselective oxidation of propranolol enantiomers by human CYP2D6, cynomolgus monkey CYP2D17 and marmoset CYP2D19. Chem Biol Interact 2011;189(3):146–152. doi: 10.1016/j.cbi.2010.12.014.
29.Ishizaki A, Saito K, Hanioka N, Narimatsu S, Kataoka H. Determination of polycyclic aromatic hydrocarbons in food samples by automated on-line in-tube solid-phase microextraction coupled with high-performance liquid chromatography-fluorescence detection. J Chromatogr A 2010;1217(35):5555–5563. doi: 10.1016/j.chroma.2010.06.068.

30.Hanioka N*, Tanabe N, Jinno H, Tanaka-Kagawa T, Nagaoka K, Naito S, Koeda A, Narimatsu S. Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci 2010;87(7–8):261–268. doi: 10.1016/j.lfs.2010.07.001.

31.Hanioka N*, Matsumoto K, Saito Y, Narimatsu S. Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. Basic Clin Pharmacol Toxicol 2010;107(1):565–569. doi: 10.1111/j.1742-7843.2010.00543.x.

32.Hanioka N*, Yamamoto M, Tanaka-Kagawa T, Jinno H, Narimatsu S. Functional characterization of human cytochrome P450 2E1 allelic variants: in vitro metabolism of benzene and toluene by recombinant enzymes expressed in yeast cells. Arch Toxicol 2010; 84(5):363–371. doi: 10.1007/s00204-009-0504-1.

33.Shimizudani T, Nagaoka K, Hanioka N, Yamano S, Narimatsu S. Comparative study of the oxidation of propranolol enantiomers in hepatic and small intestinal microsomes from cynomolgus and marmoset monkeys. Chem Biol Interact 2010; 183(1): 67–78. doi: 10.1016/j.cbi.2009.10.007.

34.Kuze J, Mutoh T, Takenaka T, Morisaki K, Nakura H, Hanioka N, Narimatsu S. Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice. Xenobiotica 2009;39(11):871–880. doi: 10.3109/00498250903215382.

35.Nonaka Y, Saito K, Hanioka N, Narimatsu S, Kataoka H. Determination of aflatoxins in food samples by automated on-line in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry. J Chromatogr A 2009;1216(20):4416–4422. doi: 10.1016/j.chroma.2009.03.035.

36.Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J. Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica 2009;39(2):140–147. doi: 10.1080/00498250802617746.

37.Narimatsu S, Kazamori D, Masuda K, Katsu T, Funae Y, Naito S, Nakura H, Yamano S, Hanioka N. The mechanism causing the difference in kinetic properties between rat CYP2D4 and human CYP2D6 in the oxidation of dextromethorphan and bufuralol. Biochem Pharmacol 2009;77(5):920–931. doi: 10.1016/j.bcp.2008.11.006.

38.Hanioka N*, Naito T, Narimatsu S. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 2008;74(1):33–36. doi: 10.1016/j.chemosphere.2008.09.053.

39.Hanioka N*, Hayashi K, Shimizudani T, Nagaoka K, Koeda A, Naito S, Narimatsu S. Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: the role of human hepatic UDP-glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7. Pharmacology 2008;82(4):293–303. doi: 10.1159/000165100.

40.Katsu T, Tsunamoto Y, Hanioka N, Komagoe K, Masuda K, Narimatsu S. A caffeine-sensitive membrane electrode: previous misleading report and present approach. Anal Chim Acta 2008;620(1–2):50–54. doi: 10.1016/j.aca.2008.05.027.

41.Hanioka N*, Takeda Y, Tanaka-Kagawa T, Hayashi K, Jinno H, Narimatsu S. Interaction of bisphenol A with human UDP-glucuronosyltransferase 1A6 enzyme. Environ Toxicol 2008;23(3):407–412. doi: 10.1002/tox.20345.

42.Hanioka N*, Tsuneto Y, Saito Y, Maekawa K, Sawada J, Narimatsu S. Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae. Basic Clin Pharmacol Toxicol 2008;102(4):388–393. doi: 10.1111/j.1742-7843.2008.00222.x.
Narimatsu S, Kiryu K, Yonemoto R, Yoshino M, Kobatake M, Kazamori D, Hagino S,
43.Masuda K, Katsu T, Asanuma M, Kumamoto T, Ishikawa T, Funae Y, Yamano S, Hanioka N, Naito S. The roles of amino acid residues at positions 216 and 219 in the structural stability and metabolic functions of rat cytochrome P450 2D1 and 2D2.Chem, Biol Interact 2008;172(1):11–21. doi: 10.1016/j.cbi.2007.11.010.

44.Narimatsu S, Yonemoto R, Masuda K, Katsu T, Asanuma M, Kamata T, Katagi M, Tsuchihashi H, Kumamoto T, Ishikawa T, Naito S, Yamano S, Hanioka N. Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2008;75(3):752–760. doi:10.1016/j.bcp.2007.09.019.

外部競争的研究資金

【2008年以降】
1.科学研究費(挑戦的研究・萌芽)(日本学術振興会):化学物質の個別化リスク評価法の開発:人工カクテル異物代謝酵素を用いる戦略,2018~2021年.

2.科学研究費(基盤研究B)(日本学術振興会):異物代謝酵素に着眼した化学物質の暴露経路依存的なリスク評価法の構築,2014~2017年.

3.住友財団・環境研究助成:人工カクテル異物代謝酵素を用いる環境汚染物質のハイスループット毒性評価法の構築,2013~2014年.
4.科学研究費(基盤研究C)(日本学術振興会):異物代謝能の個人差を考慮した化学物質のリスク評価法の開発研究,2011~2014年.

5.科学研究費(基盤研究C)(日本学術振興会):化学物質の個別化危険度評価を目指した異物代謝能の個人差発現の解明,2008~2011年.

著書及び総説

【2008年以降】
1.埴岡伸光:衛生薬学新論(編集:新井洋由,成松鎭雄,山田英之),“疾病予防と健康管理",pp. 126-145,南山堂,2012年.

入試情報 ADMISSION